Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q3 2022 · 10-Q
Revenue$390.40M$390.40M−5.6% vs Q3 2021 Net Income$36.16M$36.16M−13.9% vs Q3 2021 EPS Diluted$3.27$3.27−8.1% vs Q3 2021 Gross Profit$282,849,000−7.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flowderived$55,396,000+250.6% Free Cash Flowderived$53,628,000+891.1% Margins · derivedGross margin72.5%−1.8 pt vs Q3 2021
Operating margin12.3%−1.0 pt vs Q3 2021
Net margin9.3%−0.9 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end